Management Now Owns 51.24% of Outstanding Shares

YOUNGSVILLE, LA / ACCESSWIRE / June 25, 2015 / (OTC: IDNG) – Independence Energy Corp. (the “Company”) announced today that Beechwood Properties, LLC has agreed to increase its ownership stake in the Company to 35.39%. Combined with the ownership stake of the Schreiber Family Trust, Daniel J. Schreiber, the Company’s Chief Executive Officer, and G. Darcy Klug, the Company’s Chief Financial Officer, now beneficially own 51.24% of the Company’s outstanding shares of common stock.

This release may contain forward-looking statements. Forward-looking statements are all statements other than statements of historical fact. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. The words “anticipate,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,” “to be,” “potential” and any similar expressions are intended to identify those assertions as forward-looking statements.

Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties. In evaluating forward-looking statements, you should consider the various factors which may cause actual results to differ materially from any forward-looking statements including those listed in the “Risk Factors” section of our latest 10-K report. Further, the Company may make changes to its business plans that could or will affect its results. Investors are cautioned that the Company will undertake no obligation to update any forward-looking statements.

Media Contact:

Julie Calzone
(337) 235-2924
jcalzone@calzone.com

Company Contacts:

Daniel J. Schreiber, CEO
(858) 509-8800

G. Darcy Klug, CFO
(337) 269-5933

SOURCE: Independence Energy Corp.

ReleaseID: 430152

NEW YORK, NY / ACCESSWIRE / June 25, 2015 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.

The note is available here: DMPI June 2015 Update. SeeThruEquity is an approved equity research contributor on Thomson First Call, CapitalIQ, FactSet, and Zack’s. The report will also be available on these platforms. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

“DMPI’s lead compound, VAL-083, is a potential new treatment for refractory and front-line glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 is a first-in-class small molecule with a novel alkylating agent that has been assessed in over 40 National Cancer Institute-sponsored clinical and pre-clinical trials showing the compound has potential for multiple cancers including brain, lungs, blood, and cervical. VAL-083 has also been approved in China for the treatment of lung cancer and chronic myeloid leukemia, a cancer of white blood cells. DMPI recently presented promising data from its ongoing Phase I/II trial for VAL-083 in patients with refractory GBM at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, IL. We were encouraged by the efficacy data and continue see DMPI as one of the most overlooked stories in our biotechnology universe. We are maintaining our 12 month price target of $4.53 per share,” commented Ajay Tandon, CEO of SeeThruEquity.

Additional highlights from the update note are as follows:

Encouraging efficacy data presented at ASCO

On June 1, 2015, DMPI presented updated data from its Phase I/II clinical study of VAL-083 in patients with refractory GBM. The results of the clinical study titled, “Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma,” were presented during the Central Nervous System Tumor session, and demonstrated encouraging efficacy results, including:

– Improved overall survival (OS) rates 59% of patients treated with VAL-083 surviving longer than predicted following initiation of bevacizumab therapy.
– The median OS receiving VAL-083 at doses >30mg/m2 was about 9.0 months, offering the potential for a significant survival benefit for refractory GMB patients.
– DMPI also confirmed that it would pursue an expansion cohort of up to 14 patients at the well-tolerated dose of 40 mg/m2/day x 3 in a 21 day cycle, as well as a smaller expansion cohort at 45 mg/m2/day x 3 in a 21 day cycle to gain additional safety and efficacy information of VAL-083 at the dosing regimen being considered for advancement into later-stage clinical trials.

Large market potential for GBM

We note that GBM is the most common and deadly form of brain cancer and represents a significant unmet need. The condition affects approximately 15,000 adults each year and has a survival rate of 4.5 months without treatment and approximately half of patients’ tumors fail all other treatments – which currently include surgical debulking, Temodar(R) + radiation, and Avastin(R). Indeed, the 5-year overall survival rate is less than 3%. DMPI estimates the current annual market opportunity for VAL-083 for refractory and front-line GBM is in excess of $1Bn per year.

Please review important disclosures on our website at www.seethruequity.com.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company’s lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI), and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action. For more information, please visit http://www.delmarpharma.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson Reuters One (First Call), CapitalIQ, FactSet, Zacks and distributes its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 430139

Cannabis Protective Intelligence Network System (CPINS) Fills Major Industry Void with Collaborative Intelligence, Reporting and Investigative Platform

DENVER, CO / ACCESSWIRE / June 25, 2015 / Sy Alli, Director of Corporate Security for Dixie Brands Inc., has partnered with Bryan Fath, President of Seattle/Tacoma-based Olympus Consulting Group, to create the world’s first protective intelligence program developed exclusively for the cannabis industry. Designed to fill a significant information gap in what has historically been a “below the radar” industry, the Cannabis Protective Intelligence Network System (CPINS) will provide valuable subscription intelligence services to Cannabis related businesses. Typical of services offered in other industries that have high potential for theft and crime, the subscription will allow participating companies access to security concerns both locally, and nationally, related to their business. In addition, they will have access to CPINS investigative teams and resources along with basic services such as employee verification and background checks. These comprehensive services will allow cannabis businesses to staff appropriately and approach the safety and security of their employees and company assets, in a proactive rather than reactive fashion.

“The cannabis space has lacked a sufficient forum to create and share valuable security intelligence involving the day-to-day operations of the cannabis industry,” Alli said. “The simple things, such as employees being terminated for theft and being allowed to move on to another cannabis company, these are the types of actions that should be cataloged and noted throughout the cannabis space.”

“This intelligence program is unique to the cannabis industry in part because law enforcement and cannabis business owners can be hesitant to engage with one another,” commented Fath. “The CPINS program will bridge that gap and will bring real value to both sides of that equation, as all cannabis businesses enrolled in CPINS will have constant access to information that is critical to the security and safety of their respective operations.”

CPINS Offering

Companies that enroll in the CPINS program will have two options/price points to choose from initially. Both Tiers (listed below) will include baseline services of suspicious activity reporting, suspicious vehicle tracking, cannabis industry news and asset protection/loss prevention program development.

Additional inclusions are as follows:

Tier 1: $500/mo ($1,180 value)
– 20 background checks
– 30 vehicle plate checks

Tier 2: $1,500/mo ($2,815 value)
– 15 hours of investigation included
– 30 background checks
– 40 plate checks

“As one of the more visible companies in the cannabis space, security has always been a top concern for Dixie,” said Tripp Keber, CEO of Dixie Brands, Inc. “We are very proud to be a partner and founding member of CPINS, and to share this incredibly important platform that was developed in part by Dixie’s Director of Corporate Security, with the rest of the industry. It is through the safety, compliance and proactive thinking offered by CPINS that our industry and those within it, will achieve true security and long-term success.”

Alli and Fath are available for interviews on the security needs of the cannabis industry. The two have a combined 40 years in the security and protective services industry and are both currently involved in providing security and consulting in the cannabis industry.

ABOUT DIXIE BRANDS, INC.

Located in Denver, Colorado, Dixie Brands, Inc., (Dixie) through its affiliates across the country, has been formulating and producing award-winning THC-infused products since 2009. What began as a single flagship product, the Dixie Elixir (a THC-infused soda), has now expanded to over 30 different products across over 100 SKUs, representing the industry’s finest edibles, tinctures, topicals and connoisseur grade extractions. To find out more about Dixie’s innovative products, or about how Dixie is building the future of cannabis, please visit us at http://www.dixieelixirs.com. Remember-you must be 21 to visit our site, as cannabis products are not for those under the age of 21!

ABOUT OLYMPUS CONSULTING GROUP

The Olympus Consulting Group (OCG) is a licensed and insured security intelligence agency based in the greater Seattle area, but we serve clients on a domestic and global scale. The foundations of our agency are accountability and client communication. We pride ourselves in consistently providing our clients with personalized, advanced solutions that cannot be obtained at conventional private detective agencies.

We serve corporations, attorneys and investment firms throughout the country. OCG has vast international resources that allows us to retrieve global intelligence efficiently and cost effectively. Our goal is to consistently provide unbiased, factual information along with indisputable documentation. Our staff includes highly trained and experienced individuals with expertise in government intelligence services, criminal justice, security administration and computer science. To learn more, please visit us at http://olympusconsultinggroup.org.

Contact: Sy Alli
Phone: 720-361-4112
Email: salli@dixieelixirs.com

SOURCE: Dixie Brands, Inc.

ReleaseID: 430116